Granulomatous Lung Disease: Causes, Symptoms & Diagnosis

Granulomatous lung disease is not a single condition but a family of disorders united by one feature: the formation of granulomas, tiny clusters of immune cells that wall off something the body perceives as a threat. The list of things that can trigger these clusters is long, spanning infections like tuberculosis and certain fungi, autoimmune conditions like sarcoidosis, occupational exposures like beryllium dust, and even some cancer medications. Because so many different causes produce the same basic tissue reaction, pinning down the right diagnosis often requires piecing together imaging, tissue samples, lab tests, and the patient’s personal and occupational history.

Infectious Causes

Infections are among the most common triggers. Mycobacteria, the group of bacteria that includes tuberculosis (TB) and nontuberculous mycobacteria (NTM), are classic causes. Both TB and NTM prompt granuloma formation as a core part of the immune response to contain the bacteria.¹ In TB specifically, the bacterium has evolved to push the immune system toward forming necrotizing granulomas, structures whose centers break down into a cheese-like dead tissue. These granulomas can eventually erode into the airways, allowing the bacteria to spread to new hosts through coughing.² NTM infections, which are increasingly recognized in people with structural lung problems or weakened immunity, produce granulomas that can look similar but tend to follow somewhat different patterns under the microscope.

Fungi are the other major infectious culprit. In certain parts of the world, inhaling spores of specific fungi leads to granulomatous reactions in the lungs. Histoplasmosis, caused by Histoplasma capsulatum, and coccidioidomycosis, caused by Coccidioides species, are the best-known examples. Both can range from mild, self-limited respiratory illness to chronic or disseminated disease, and both produce granulomas that can persist as calcified nodules long after the active infection has cleared.³ These old granulomas are a frequent cause of incidental lung nodules found on CT scans done for unrelated reasons, which then need to be distinguished from cancer.

Sarcoidosis and Other Non-Infectious Causes

Sarcoidosis is the most common non-infectious granulomatous lung disease, and in many countries it is the single most frequent cause of pulmonary granulomas overall. Its hallmark is the non-caseating granuloma, a well-organized cluster of immune cells that does not develop the central necrosis seen in TB.⁴ The cause of sarcoidosis remains unknown, though current thinking points to an exaggerated immune response to one or more environmental antigens in genetically susceptible people. It can affect virtually any organ, but the lungs and the lymph nodes in the chest are involved in the vast majority of cases.

Hypersensitivity pneumonitis, sometimes called “farmer’s lung” or “bird fancier’s lung” depending on the exposure, is another non-infectious cause. In this condition, repeated inhalation of organic dusts, mold spores, or animal proteins triggers granuloma formation centered around the small airways. Chronic beryllium disease is an occupational counterpart: workers exposed to beryllium dust or fumes in industries like aerospace, electronics manufacturing, or nuclear energy can develop an immune sensitization that leads to well-formed lung granulomas virtually indistinguishable from sarcoidosis.⁵ One case report highlights just how easily beryllium disease can be missed: a woman spent years being treated for hypersensitivity pneumonitis and eventually needed a lung transplant before a detailed occupational history and post-transplant testing confirmed beryllium sensitization as the true cause.⁶

Autoimmune Vasculitis and the Lungs

Granulomatosis with polyangiitis (GPA, formerly called Wegener’s granulomatosis) is an autoimmune small-vessel vasculitis that primarily targets the respiratory tract and kidneys. Granulomas form in and around blood vessel walls, leading to tissue destruction. Lung involvement can produce nodules, cavities, or areas of bleeding.⁷ A related condition, eosinophilic granulomatosis with polyangiitis (EGPA, formerly Churg-Strauss syndrome), also causes granulomatous inflammation in the lungs but typically in the context of severe asthma and high eosinophil counts. Refractory cases of EGPA have shown promising responses to targeted biologic therapies like mepolizumab.⁸

Drug-Induced Granulomas

A newer addition to the list of causes involves immune checkpoint inhibitors, cancer drugs that unleash the immune system against tumors. These medications can occasionally provoke a granulomatous reaction in the lungs that closely resembles sarcoidosis on imaging and biopsy. This reaction typically shows up as a focal area of consolidation, often round or nodular, without the enlarged lymph nodes you would expect in true sarcoidosis. Patients are usually asymptomatic despite the visible lung changes, and the findings tend to resolve on their own once the checkpoint inhibitor is paused.⁹ In rare instances, checkpoint inhibitors can also reactivate dormant granulomatous infections in people who had previous exposure to organisms like fungi or mycobacteria.¹⁰

This matters for oncologists and patients alike because these granulomatous reactions can be mistaken for cancer progression on imaging. A new or growing nodule in someone undergoing cancer treatment naturally raises alarm, and correctly identifying it as a drug side effect rather than advancing disease changes management entirely.

Granulomatous Lung Disease in Immunodeficiency

Paradoxically, people with certain immune deficiencies are also prone to developing granulomas in the lungs. Common variable immunodeficiency (CVID), the most frequent symptomatic primary antibody deficiency, can lead to a complication called granulomatous-lymphocytic interstitial lung disease (GLILD). This is a distinct pattern in which granulomas and lymphoid tissue infiltrate the lung, gradually impairing breathing function.¹¹ Patients with GLILD tend to have more splenomegaly, autoimmune blood cell destruction, and bronchiectasis than CVID patients without lung involvement.¹²

Chronic granulomatous disease (CGD) is a different story. This inherited condition disables the oxidative burst that white blood cells normally use to kill ingested bacteria and fungi. The result is severe, recurrent infections and an exaggerated inflammatory response that produces granulomas.¹³ In children with CGD, recurrent lung infections are the most common problem, and complications can include abscesses, bronchiectasis, and spread of infection beyond the lungs.¹⁴

Symptoms and How They Vary

Granulomatous lung diseases as a group are remarkably variable in how they present. Some people have obvious respiratory complaints: a persistent cough, shortness of breath on exertion, or chest discomfort. Others are completely asymptomatic, and the granulomas are discovered incidentally on an imaging study done for something else. Constitutional symptoms like fatigue, low-grade fever, night sweats, and unexplained weight loss can accompany infectious causes like TB or disseminated fungal disease, and sometimes sarcoidosis as well.

What makes clinical presentation particularly tricky is that the symptoms rarely point to a specific cause. A dry cough with bilateral lymph node enlargement could be sarcoidosis, lymphoma, or TB. Nodules with cavities could be GPA, cancer, or a fungal infection. Miliary (diffuse tiny-nodule) patterns on imaging can show up in disseminated TB, sarcoidosis, or metastatic cancer. The clinical picture alone almost never settles the diagnosis.¹⁵

What Imaging Can and Cannot Tell You

High-resolution CT scanning is the primary imaging tool, and the distribution pattern of granulomas offers real diagnostic clues. Granulomas that follow the lymphatic pathways, clustering along the airways, blood vessels, and the lining of the lung, are the classic pattern in sarcoidosis. A random, scattered distribution of tiny nodules suggests something spread through the bloodstream, with miliary TB being the textbook example. Granulomas centered on the small airways point toward hypersensitivity pneumonitis or an infection that spread via the bronchial tree.¹⁶

In GPA, CT findings can include nodules that may develop central cavities, ground-glass areas from bleeding into the lung, and narrowing or ulceration of the airways.¹⁷ These features overlap enough with cancer and infection that imaging alone is seldom definitive. One study found that primary lung cancer and granulomatous nodules can have identical CT imaging features, making it impossible to distinguish them on appearance alone in some cases.¹⁸

PET/CT scans, which measure metabolic activity, add another dimension. Active granulomas are metabolically hungry and light up on PET scans just as cancers do. In areas where granulomatous infections are common, the standard PET threshold for distinguishing benign from malignant nodules keeps its high sensitivity (above 95%) but loses specificity because inflamed granulomas generate false positives.¹⁹ Where PET/CT has found a more reliable role is in monitoring disease activity in sarcoidosis. In one study of patients with active chronic sarcoidosis, PET/CT detected active disease in about four out of five patients, and a positive PET result was significantly associated with a subsequent change in therapy, regardless of what conventional markers like blood ACE levels showed.²⁰

Getting to a Definitive Diagnosis

Because imaging overlaps so heavily across causes, tissue sampling is often essential. Standard pathology, including microscopic examination, special stains for organisms, and culture, remains the foundation. But these methods have real limitations: organisms may be present in very low numbers, prior antibiotic or antifungal treatment may suppress growth in culture, and small biopsy samples may simply miss the pathogen.²¹ Molecular techniques, including PCR testing and next-generation sequencing, are increasingly used to fill these gaps, identifying pathogens at the species level even when traditional methods come up empty.

For sarcoidosis specifically, endobronchial ultrasound-guided needle aspiration (EBUS-TBNA) has become a go-to diagnostic procedure. This minimally invasive technique uses ultrasound from inside the airways to guide a needle into enlarged lymph nodes. In one study, EBUS-TBNA achieved a diagnostic accuracy above 91% for sarcoidosis, significantly outperforming older bronchoscopic methods, especially in patients whose disease was limited to lymph node enlargement without obvious lung infiltrates.²²

The broader diagnostic lesson is that a granuloma by itself tells you remarkably little. The same review that catalogued the enormous range of possible causes, from mycobacteria and fungi to sarcoidosis, berylliosis, vasculitis, and several rarer conditions, emphasized that a multidisciplinary approach combining pathology, radiology, clinical context, and laboratory data is essential for confident diagnosis.¹⁵

Why Geography Matters

Where you live or have traveled can sharply shift the probability of different causes. A retrospective study of 500 cases of pulmonary granulomas from seven countries found striking geographic differences: mycobacteria accounted for about 19% of cases outside the United States but only 8% within it, while fungi caused 19% of cases inside the U.S. versus just 4% elsewhere.²³ This reflects the geographic concentration of endemic fungi like Histoplasma in the Ohio and Mississippi River valleys and Coccidioides in the desert Southwest, versus the global distribution of TB, which is far more prevalent outside North America.

For clinicians, this means the diagnostic workup should be tailored to where the patient has lived and worked. A granulomatous nodule in someone from rural Ohio calls for a fungal workup that might not be high on the list for a patient in Scandinavia, where sarcoidosis and TB dominate. Travel history and occupational exposure history are not just check-the-box questions in this context; they directly shape which tests get ordered and how the results are interpreted.

Treatment Depends Entirely on the Cause

There is no single treatment for granulomatous lung disease because there is no single disease. Infectious causes get targeted antimicrobial therapy: antibiotics for TB, antifungals for histoplasmosis or coccidioidomycosis. For autoimmune or inflammatory causes like sarcoidosis, corticosteroids have long been the first-line treatment to tamp down the granulomatous inflammation.²⁴ But corticosteroids carry significant side effects over time, and for patients who cannot taper to acceptable doses or who develop steroid-related complications, several steroid-sparing options now have growing evidence behind them, including methotrexate, azathioprine, and biologic agents.

For GPA and EGPA, immunosuppressive therapy is the cornerstone, sometimes combined with plasma exchange in severe cases. Beryllium disease currently has no cure; treatment focuses on reducing inflammation and avoiding further exposure. Drug-induced granulomatous reactions from checkpoint inhibitors often resolve simply by pausing the offending medication. The common thread is that getting the treatment right depends on getting the diagnosis right first, which loops back to the challenge at the center of this entire group of diseases.

What Happens Inside a Granuloma

The immune cells inside a granuloma are not passive bystanders. In tuberculosis, for instance, the balance between different cell types determines whether the granuloma stays stable or deteriorates. Research using detailed tissue staining has found that solid, non-necrotic granulomas contain elevated numbers of myeloid-derived suppressor cells (a type of immune cell that dampens inflammation), along with increased expression of immunosuppressive molecules. The suggestion is that these suppressor cells may actually contribute to the granuloma’s eventual breakdown into a necrotic lesion, worsening the disease and promoting bacterial spread.²⁵ This is an area where the science is still early, but it challenges the simple view that granulomas are purely protective structures. In some circumstances, the immune system’s own response contributes to tissue damage.

Ongoing research into granuloma biology is not purely academic. Understanding what makes a granuloma progress or regress could eventually lead to therapies that modulate the immune response more precisely, pushing granulomas toward resolution rather than simply suppressing the entire immune system with broad-acting drugs like steroids. For now, this remains a research frontier, but it is one reason why pulmonary granulomatous disease continues to attract intense scientific interest despite being recognized for well over a century.